boltbio.com (BOLT) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
This EV/EBITDA chart for Bolt Biotherapeutics (BOLT), with a value of 0.00, reflects the price action of a company developing antibodies for the targeted destruction of tumors, where partnerships with industry behemoths mitigate development risks. The business relies on collaborations with clinics and royalty payments for immune response activation methods. High demand is driven by a severe shortage of effective treatments within the targeted oncology segment.
boltbio.com - analytical breakdowns and key metrics (BOLT)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Bolt Biotherapeutics|BOLT - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Bolt Biotherapeutics, Inc.|BOLT - Company Cumulative Debt|Debts to Book Capitalization Bolt Biotherapeutics|BOLT - Company Long-Term Debt|Company Short-Term Debt Bolt Biotherapeutics|Quick Liquidity boltbio.com
- business earnings and investment ratios data:
BOLT - Company Net Income|Future Profit Bolt Biotherapeutics|BOLT - Market Price to Net Income Ratio|Projected Price to Earnings Bolt Biotherapeutics, Inc.|BOLT - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Bolt Biotherapeutics|BOLT - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Bolt Biotherapeutics|BOLT - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months boltbio.com|BOLT - Earnings per share growth rate in current year|Expected earnings per share growth for next year Bolt Biotherapeutics
Initial company analysis:Bolt Bio BOLT
The EV/EBITDA multiple compares the total enterprise value of a business with its operating profit before interest and taxes, determining the investment payback period while accounting for debt load. By analyzing the EV/EBITDA valuation trend, an investor can see how the patent protection of the ISAC platform and strict FDA oversight impact the capitalization of Bolt Biotherapeutics (BOLT), transforming a technological barrier into the foundation of long-term investment attractiveness.
Who Bolt Biotherapeutics competes with
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|Vera Pharma - EV/EBITDA Multiple|DNTH: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Pharvaris N.V. (PHVS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA AbCellera (ABCL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tourmaline Bio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PGEN|Enterprise Value to EBITDA Ratio PHAR (Pharming)|Enterprise Value to Operating Income Before Depreciation Ratio NKTR|Upstream Bio Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ZBIO|Immunome - EV/EBITDA Multiple|GOSS: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|KALV: EV/EBITDA Multiple|SEPN - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals|Company Value to EBITDA savarapharma.com SVRA|Enterprise Value to EBITDA Ratio RIGL (Rigel Pharmaceuticals, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ANAB|EV/EBITDA Multiple ATXS (Astria Pharma)|Business Value to Operating Income Before Depreciation ENGN|RAPT Therapeutics - EV/EBITDA Multiple|Company Value to EBITDA Aerovate Therapeutics Inc|Aclaris Therapeutics, Inc. (ACRS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Kyverna Therapeutics Inc. - Business Value to Operating Income Before Depreciation|TLSA (Tiziana Life Sciences PLC) - EV/EBITDA Multiple|EV/EBITDA Multiple Cabaletta Bio Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ventyx Biosciences (VTYX)|THTX: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple AVTX (Avalo Therapeutics)|Eledon Pharmaceuticals Inc. (ELDN) - Company Value to EBITDA|AGEN: Enterprise Value to EBITDA Ratio|CLYM - EV/EBITDA Multiple|ZURA (Zura Bio) - Enterprise Value to EBITDA Ratio|ATYR: Enterprise Value to Operating Income Before Depreciation Ratio|ADAG (Adagene Inc) - EV/EBITDA Multiple|Ikena Oncology, Inc. (IMA) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple STTK|Enterprise Value to EBITDA Ratio equilliumbio.com EQ|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Connect Biopharma Holdings Limited CNTB|Total Company Value to Operating Income Before Depreciation Ratio Immunic Therapeutics (IMUX)|Atara Biotherapeutics Inc - EV/EBITDA Multiple|IFRX: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|X4 Pharma (XFOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Adicet Bio, Inc. (ACET)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Celularity Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization INMB|Enterprise Value to EBITDA Ratio BRNS (Barinthus Biotherapeutics plc)|Enterprise Value to Operating Income Before Depreciation Ratio KZR|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SAB Biotherapeutics, Inc SABS|AKTX (Akari Therapeutics, Plc) - Company Value to Operating Income Before Depreciation Ratio|Enlivex Therapeutics, Ltd. - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation QTTB (Q32 Bio Inc.)|GOVX: EV/EBITDA Multiple|Edesa Biotech Inc (EDSA) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iBio Corp|CARM: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization XTL Biopharmaceuticals (XTLB)|Enterprise Value to EBITDA Ratio hcwbiologics.com HCWB|EV/EBITDA Multiple APVO (Aptevo Therapeutics Inc.)|EV/EBITDA Multiple aimimmuno.com AIM|ADTX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation GRI (GRI Bio Corporation)|XRTX: EV/EBITDA Multiple|HIND - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Revelation Biosciences, Inc.|Enterprise Value to EBITDA Ratio Indaptus Therapeutics Inc (INDP)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Scinai (SCNI)|Enterprise Value to EBITDA Ratio calcimedica.com CALI|Affimed N.V. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Allakos Inc ALLK|HOOK - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IGMS (IGM Biosciences, Inc.) - Enterprise Value to Operating Income Before Depreciation|ITOS: EV/EBITDA Multiple|Company Value to EBITDA Ocean Biomedical Corp (OCEA)|TCBP (TC Biopharm) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization THRD
